Business Wire

Adtran wins two FTTH Innovation Awards for 50G PON and deep PON fiber monitoring

27.3.2025 16:00:00 CET | Business Wire | Press release

Share

News summary: Adtran’s 50G PON fiber access solution and fiber monitoring platform recognized for their impact on advancing fiber broadband connectivity SDX 6405 OLT supports coexistence of GPON, XGS-PON and 50G PON on each port for seamless network scaling ALM with deep PON assurance delivers real-time, in-service fiber monitoring, enhancing network reliability and reducing opex costs

Adtran today announced that it has won two FTTH Innovation Awards at the FTTH Conference 2025, recognizing its SDX 6405 optical line terminal (OLT) and ALM fiber monitoring platform as standout technologies supporting next-generation fiber networks. Organized by the FTTH Council Europe, the annual awards highlight innovations that accelerate fiber broadband rollouts while improving scalability, operational efficiency and user experience. Adtran received awards in two categories: ‘Active infrastructure – central network’ and ‘Installation equipment, tools, test & measurement instruments.’

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326874284/en/

Adtran’s SDX 6405 OLT and ALM fiber monitoring platform received Innovation Awards at the FTTH Conference 2025.

“We’re honored to receive this recognition at the FTTH Conference. It’s a fantastic achievement for our team and a validation of the vision that’s guided our work: to help service providers build fiber networks that are open, scalable and ready for what comes next,” said Christoph Glingener, CTO of Adtran. “These wins reflect the dedication and expertise across our organization – from engineering to product to field support – and the close partnerships we’ve built with customers to solve real deployment challenges. Whether it’s enabling a future-proof transition to 50G PON or delivering affordable, real-time visibility into the access network, we’re focused on giving operators the tools to grow efficiently, improve reliability and stay ahead of demand.”

Adtran’s SDX 6405 won in the central network category for its 50G PON capabilities and disaggregated architecture. Part of the SDX 6000 Series, it supports GPON, XGS-PON and 50G PON on every port, enabling providers to deliver multigigabit services for residential, business and backhaul use cases – all over a single fiber. Its modular design eliminates the trade-off between near-term cost and long-term scalability. With the SDX 6405, providers can gradually add 50G OLTs to meet growing demand without disrupting existing subscribers or overhauling infrastructure. Built on an open, software-defined architecture, it integrates seamlessly into multivendor networks and supports automated service delivery through Adtran’s Mosaic Cloud Platform.

In the tools and measurement category, Adtran’s ALM was recognized for redefining how service providers monitor and manage fiber infrastructure. The compact, low-power device offers real-time, in-service visibility across the entire optical plant – enabling operators to detect and pinpoint issues before they affect customers. A key innovation is its deep PON assurance capability, which makes it possible to monitor fiber behind splitters without the need for demarcation reflectors. This is especially valuable for FTTH deployments, where scale and complexity can make fault detection and resolution a significant operational challenge. With support for fixed and mobile access networks, ALM empowers operators to increase service quality while lowering operational costs.

“These two awards recognize technologies that are solving critical challenges in access networks – from scaling bandwidth to ensuring new levels of service reliability,” commented Robert Conger, GM of software platforms and strategy at Adtran. “With 50G PON, we’re enabling a new generation of services that demand ultra-fast, highly reliable connectivity – whether that’s AI workloads, immersive experiences or industrial automation. At the same time, it delivers lower-speed services like 1G and 10G far more efficiently, helping operators simplify their access infrastructure and maximize return on investment. And with deep PON assurance, we’re giving operators the visibility they need to maintain those services at scale. It’s about building the foundation for sustainable, high-performance broadband that can evolve with demand.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250326874284/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye